|
Belgium is a significant European location for clinical trials and has always played a major role in international clinical research. Reflecting this, Kendle has extended its global clinical development capabilities in the country, building on our strong operational base in Western Europe.
Belgium’s long history of clinical research and high standards of medical care have shaped its strong current trial environment. Around 150 pharmaceutical companies have operations in the country, and they produce 5 percent of all new medicines worldwide. Researchers in Belgium also conduct the largest number of clinical trials per capita in Europe.
Economy and expertise
Belgium offers two highly competitive advantages in clinical research over its neighbours: the lowest clinical trial costs of any European Union country, coupled with trial investigators with considerable experience in clinical research. The country has 16 university centers, an extensive network of scientific institutes and more than 3,000 researchers working in pharmaceutical research and development.
In 2004, a new Belgian law on experiments involving human subjects reinforced Belgium’s attractive position to pharmaceutical companies. Through this, Belgium continues to provide one of the quickest European regulatory environments for Phase I-IV trials. Both the competent ethics committee and the Directorate General of Medicinal Products are required to complete their respective reviews rapidly – within 15 days for Phase I trials and 28 days for regular Phase II to IV trials.
- Cardiovascular
- CNS
- Infectious disease (HIV)
- Oncology
- Ophthalmology
- Respiratory
- Vaccines
- Pediatrics
|
